title: [Therapy for patients with primary refractory and relapsed Hodgkin-lymphoma--our experience].
abstract: Recovery have been achieved in the majority of Hodgkin-lymphoma patients. Unfortunately some of the patients refracter and about third of the patients relapsed after the first-line treatment.
  
  
  OBJECTIVE
  We investigated the frequency and treatment of refracter or relapsed Hodgkin lymphoma patients between 1996 and 2006.
  
  
  RESULTS
  We examined 76 women and 71 men, who had HL in this period. 141 patients (95,9%) had remission after first-line therapy. 6 women were primary refracter, 4 of them had high-dose therapy and autolog stem cell transplantation. They died in spite of the multiple treatment. 31 patients - 13 men and 18 women - had relapse (16 cases were in one year). 14 patients had high-dose therapy and autolog stem cell transplantation, 11 patients had only chemotherapy, 3 had only radiotherapy and 3 patients were treated by combined modality treatment. 6 of the relapsed patients were died, 5 because of the progression of lymphoma and one because of secunder myelodysplasia.
  
  
  CONCLUSIONS
  Relapsed patients have a good prognosis, but refracter patients have long chance despite autolog or allogen hemopoietic stem cell transplantation. Searching for new therapeutical modalities for these patients is extremely important.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Altalános Orvostudományi Kar, Belgyógyászati Intézet, III. Belgyógyászati Klinika, Debrecen Móricz Zs., krt. 22., 4032. mil03@freemail.hu
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Miltényi
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Simon
authors.forename: Edit
authors.initials: E
authors.lastname: Páyer
authors.forename: László
authors.initials: L
authors.lastname: Váróczy
authors.forename: Lajos
authors.initials: L
authors.lastname: Gergely
authors.forename: Arpád
authors.initials: A
authors.lastname: Illés
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult